{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:51:09Z","timestamp":1771483869444,"version":"3.50.1"},"reference-count":30,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Due to increasing resistance to commonly used antibiotics, the World Health Organization and Food and Drug Administration have advocated the development of new therapeutic regimens for Helicobacter pylori (H. pylori). This phase three, double-blind study (ERADICATE Hp) randomized (2:1) treatment-na\u00efve adults with H. pylori infection and dyspepsia to RHB-105 (an all-in-one combination of omeprazole 40 mg, amoxicillin 1000 mg, and rifabutin 50 mg) or an identically-appearing placebo, both administered every 8 h for 14 days. The H. pylori eradication rate with RHB-105, using a modified intent-to-treat (mITT) population of subjects who received \u22651 dose of study drug and had test-of-eradication performed 28\u201335 days post-completion of therapy, was compared (one-sample Z-test) to a literature-derived comparator rate of 70% and success rate with physician-selected standard-of-care given to placebo failures. The mITT H. pylori eradication rate (95% CI) with RHB-105 of 89.4% (82.0\u201396.8%) was greater than both the literature-derived comparator rate (P &lt; 0.001) and the standard-of-care rate of 63.0% (44.8\u201381.1%) (P = 0.006). Adverse events with an incidence \u22655% for RHB-105 were diarrhea (12.7%), headache (11.9%), chromaturia (9.3%), abdominal tenderness (6.8%), and dizziness (5.1%). No leukopenia was noted. RHB-105 (Talicia\u00ae) proved to be a safe and effective empiric therapy for H. pylori eradication.<\/jats:p>","DOI":"10.3390\/antibiotics9100685","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T10:19:23Z","timestamp":1602238763000},"page":"685","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial"],"prefix":"10.3390","volume":"9","author":[{"given":"Ira N.","family":"Kalfus","sequence":"first","affiliation":[{"name":"Independent Consultant, M2g Consulting, 251 Central Park West, New York, NY 10024, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Y.","family":"Graham","sequence":"additional","affiliation":[{"name":"Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, 2002 Holcombe Boulevard, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis S.","family":"Riff","sequence":"additional","affiliation":[{"name":"Anaheim Clinical Trials, 1085 N. Harbor Blvd, Anaheim, CA 92801, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond M.","family":"Panas","sequence":"additional","affiliation":[{"name":"Medical Affairs, RedHill Biopharma, Inc., 8045 Arco Corporate Drive, Suite 200, Raleigh, NC 27617, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"ref_2","first-page":"26","article-title":"Epidemiology of gastric cancer: Global trends, risk factors and prevention","volume":"14","author":"Rawla","year":"2019","journal-title":"Prz. Gastroenterol."},{"key":"ref_3","unstructured":"IARC Working (1994). Group on the Evaluation of Carcinogenic Risks to Humans Schistosomes, liver flukes and Helicobacter pylori. Lyon, 7\u201314 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum., 61, 1\u2013241."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1053\/j.gastro.2019.10.019","article-title":"Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: A large cohort study","volume":"158","author":"Kumar","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_5","unstructured":"Barzilay, E.J., and Fagan, R.P. (2011). Chapter 3: Infectious Diseases Related to Travel. 2012 Yellow Book\u2014Travelers\u2019 Health\u2014CDC, Oxford University Press Inc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/aje\/kwj018","article-title":"Iron deficiency and Helicobacter pylori infection in the United States","volume":"163","author":"Cardenas","year":"2006","journal-title":"Am. J. Epidemiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/BF01297451","article-title":"Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries","volume":"36","author":"Graham","year":"1991","journal-title":"Dig. Dis Sci."},{"key":"ref_8","unstructured":"Wannmacher, L. (2011). Review of the evidence for H. pylori treatment regimens: Section 17.1 (Review)\u2014Adults and Children. World Health Organization. 18th Expert Committee on the Selection and Use of Essential Medicines."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1086\/315384","article-title":"Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States","volume":"181","author":"Everhart","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrgastro.2017.57","article-title":"Helicobacter pylori infection and antibiotic resistance: A WHO high priority?","volume":"14","author":"Dang","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"Review article: The global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"Thung","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG Clinical Guideline: Treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto consensus for the treatment of Helicobacter pylori infection in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_14","unstructured":"U.S (2019, October 05). Food and Drug Administration, Health and Human Services. Establishing a list of qualifying pathogens under the Food and Drug Administration Safety and Innovation Act. Federal Register, 5 June 2014, Available online: https:\/\/www.federalregister.gov\/documents\/2014\/06\/05\/2014-13023\/establishing-a-list-of-qualifying-pathogens-under-the-food-and-drug-administration-safety-and-innocation-act."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/AAC.45.5.1568-1571.2001","article-title":"In vitro activity of clarithromycin against intracellular Helicobacter pylori","volume":"45","author":"Piccolomini","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hays, C., Burucoa, C., Lehours, P., Tran, C.T., Leleu, A., and Raymond, J. (2018). Molecular characterization of Helicobacter pylori resistance to rifamycins. Helicobacter, 23.","DOI":"10.1111\/hel.12451"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1128\/AAC.43.6.1497","article-title":"Rifampin and rifabutin resistance mechanism in Helicobacter pylori","volume":"43","author":"Heep","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJM199807023390116","article-title":"Treatment of antibiotic-resistant Helicobacter pylori [letter]","volume":"339","author":"Perri","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/00365521.2015.1092577","article-title":"In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in central Italy","volume":"51","author":"Cataldi","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.5114\/aoms.2013.36917","article-title":"Antimicrobial susceptibility of Helicobacter pylori isolates from lower Silesia, Poland","volume":"10","author":"Biernat","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/clinids\/22.Supplement_1.S3","article-title":"Antimicrobial activity of rifabutin","volume":"22","author":"Kunin","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","first-page":"1300","article-title":"In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats","volume":"279","author":"Koudriakova","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2011.04937.x","article-title":"Review article: Rifabutin in the treatment of refractory Helicobacter pylori infection","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/QCO.0000000000000396","article-title":"Antibiotic resistance in Helicobacter pylori","volume":"30","author":"Alba","year":"2017","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0016-5085(98)70100-3","article-title":"Antibiotic resistance in Helicobacter pylori: Implications for therapy","volume":"115","author":"Graham","year":"1998","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2036.2006.02793.x","article-title":"Efficacy and safety of rifabutin-containing \u2018rescue therapy\u2019 for resistant Helicobacter pylori infection","volume":"23","author":"Borody","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infection\u2014The Maastricht IV\/Florence Consensus Report","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/hel.12258","article-title":"Treatment of Helicobacter pylori infection 2015","volume":"20","author":"Gisbert","year":"2015","journal-title":"Helicobacter"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000350719","article-title":"Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection","volume":"88","author":"Venerito","year":"2013","journal-title":"Digestion"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/M19-3734","article-title":"Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: A double-blind, randomized, controlled trial","volume":"172","author":"Graham","year":"2020","journal-title":"Ann. Intern. Med."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/10\/685\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:17:50Z","timestamp":1760177870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/10\/685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["antibiotics9100685"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics9100685","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,9]]}}}